The April 2021 scorecard for the signals generated from Jet Equities can be downloaded here.
The March 2021 scorecard for the signals generated from Jet Equities can be downloaded here.
Exela Technologies, Inc. (XELA) announced on March 9 that the company received a new $90 contract with a major US health insurance company. Exela Technologies is a global leader in business process automation and launched its PCH Global platform in September 2020 to combine its services with the power of automation technology and SaaS. This […]
The February 2021 scorecard for the signals generated from Jet Equities can be downloaded here.
On March 2, KemPharm, Inc. (KMPH) announced that the FDA approved its New Drug Application (NDA) for the drug AZSTARYS™ (formerly referred to as KP415). The drug is a once-daily treatment for patients six-years-old and above who have attention deficit hyperactivity disorder (ADHD). AZSTARYS™ should be available as early as the second half of 2021 […]
Aegean Corporation (AEGN) announced on February 16 that the company entered into a definitive agreement for an acquisition by affiliates of New Mountain Capital, LLC. Aegean’s stockholders will receive a cash payout of $26 per share, which is a 28% premium over the stock’s 30-day moving average price. The deal values the enterprise at $963 […]
Gilat Satellite Networks, Ltd. (GILT) announced on February 4 that the company was awarded a multi-million-dollar contract. Under the terms of the contract, Gilat will provide mission telecom systems for 29 airports in Peru. Gilat, a global leader in satellite-based broadband communications, has successfully completed several other large government projects in Peru. Jet Equities […]
The February 2021 scorecard for the signals generated from Jet Equities can be downloaded here.
On January 26, Sorrento Therapeutics, Inc. (SRNE) announced preliminary results from a Phase 1b study of COVID-MSC for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). COVI-MSC is an infusion treatment of human allogeneic adipose-derived mesenchymal stem cells. The three patients in the study experienced no infusion-related adverse effects […]
On January 12, IZEA Worldwide, Inc. (IZEA) announced that the company received a seven-figure contract award from a Fortune 100 retailer. The retailer is an existing client that expanded its marketing program with IZEA through 2021. Under the terms of the contract, IZEA will provide managed services and licensing of IZEA’s BrandGraph software. IZEA is […]
